News Leap Therapeutics, Inc.

Equities

LPTX

US52187K2006

Real-time Estimate Cboe BZX Other stock markets 12:57:06 2024-04-16 pm EDT			5-day change	1st Jan Change
3.06 ^USD	+2.00%		-10.85%	-26.66%

Apr. 10	Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP	CI
Mar. 19	Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Leap Therapeutics Announces $40 Million Private Placement	Apr. 11	PR
Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP	Apr. 09	CI
Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating	Mar. 19	MT
Leap Therapeutics Files $200 Million Mixed-Securities Shelf Registration	Mar. 18	MT
Leap Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 18	CI
Leap Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Transcript : Leap Therapeutics, Inc. - Special Call	Jan. 23
Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium	Jan. 16	CI
Transcript : Leap Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 01:30 PM	Jan. 10
Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	PR
Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients	Jan. 02	PR
Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients	Jan. 02	CI
Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium	Dec. 12	AQ
Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference	Nov. 21	PR
Mizuho Securities Adjusts Price Target on Leap Therapeutics to $12 From $20, Maintains Buy Rating	Nov. 20	MT
Leap Therapeutics Reports Third Quarter 2023 Financial Results	Nov. 13	PR
Leap Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Top Premarket Decliners	23-10-16	MT
Top Premarket Decliners	23-10-09	MT
Leap Therapeutics to Participate at Upcoming Investor Conferences	23-09-05	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Leap Therapeutics, Inc.

Equities

LPTX

US52187K2006

Summary

Filters